Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Wołowiec, Łukasz; Banach, Joanna; Budzyński, Jacek; Wołowiec, Anna; Kozakiewicz, Mariusz; Bieliński, Maciej; Jaśniak, Albert; Olejarczyk, Agata; Grześk, Grzegorz

doi:10.3390/jcm12134208

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research on non-traditional molecules that could delineate the relationship between the gut microbiome and CVD should also be a frontier of more extensive research. In particular, catestatin, which is a neuroendocrine hormone (chromogranin A derivative) also found in enteroendocrine cells, has a close relationship with the regulation of the GM in preclinical models [90] and has been found to correlate with all-cause death and unplanned heart failure hospitalization in patients with heart failure with reduced ejection fraction (HFrEF) [91]. Further research regarding the relationship of the GM, enteroendocrine cells, CVD and especially VHD is necessary, as it could lead to the identification of novel biomarkers that could link GM dysbiosis and cardiovascular clinical outcomes.…”

Section: Future Directionsmentioning

confidence: 99%

Gut Microbiome and Its Role in Valvular Heart Disease: Not a “Gutted” Relationship

Nayak,

Dimitriadis,

Pyrpyris

et al. 2024

Life

View full text Add to dashboard Cite

The role of the gut microbiome (GM) and oral microbiome (OM) in cardiovascular disease (CVD) has been increasingly being understood in recent years. It is well known that GM is a risk factor for various CVD phenotypes, including hypertension, dyslipidemia, heart failure and atrial fibrillation. However, its role in valvular heart disease (VHD) is less well understood. Research shows that, direct, microbe-mediated and indirect, metabolite-mediated damage as a result of gut dysbiosis and environmental factors results in a subclinical, chronic, systemic inflammatory state, which promotes inflammatory cell infiltration in heart valves and subsequently, via pro-inflammatory molecules, initiates a cascade of reaction, resulting in valve calcification, fibrosis and dysfunction. This relationship between GM and VHD adds a pathophysiological link to the pathogenesis of VHD, which can be aimed therapeutically, in order to prevent or regress any risk for valvular pathologies. Therapeutic interventions include dietary modifications and lifestyle interventions, in order to influence environmental factors that can promote gut dysbiosis. Furthermore, the combination of probiotics and prebiotics, as well as fecal m transplantation and targeted treatment with inducers or inhibitors of microbial enzymes have showed promising results in animal and/or clinical studies, with the potential to reduce the inflammatory state and restore the normal gut flora in patients. This review, thus, is going to discuss the pathophysiological links behind the relationship of GM, CVD and VHD, as well as explore the recent data regarding the effect of GM-altering treatment in CVD, cardiac function and systemic inflammation.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Gut Microbiome and Its Role in Valvular Heart Disease: Not a “Gutted” Relationship

Nayak,

Dimitriadis,

Pyrpyris

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

Enhanced Association of Novel Cardiovascular Biomarkers Fetuin-A and Catestatin with Serological and Inflammatory Markers in Rheumatoid Arthritis Patients

Pàmies,

Llop,

Ibarretxe

et al. 2024

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with increased cardiovascular disease (CVD) risk and mortality. This work aimed to evaluate the serum levels of the novel CV biomarkers fetuin-A (fet-A), Dickkopf-1 (DKK-1), galectin-3 (Gal-3), interleukin-32 (IL-32), and catestatin (CST) in RA patients and their associations with RA parameters and CVD markers. A cohort of 199 RA patients was assessed for traditional CVD risk factors, RA disease activity, and biomarker levels. Carotid ultrasound was used to measure carotid intima-media thickness (cIMT) and carotid plaque presence (cPP). Multivariate analyses examined correlations between biomarkers and RA parameters, serological markers, and CVD markers. Adjusted models showed that elevated CST expression levels were associated with rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) positivity (OR = 2.45, p = 0.0001 and OR = 1.48, p = 0.04, respectively) in the overall cohort and for RF in men and women, respectively. In addition, fet-A concentration was inversely associated with the erythrocyte sedimentation rate (ESR) in the overall cohort (β = −0.15, p = 0.038) and in women (β = −0.25, p = 0.004). Fet-A levels were also negatively correlated with disease activity (DAS28-ESR) scores (β = −0.29, p = 0.01) and fibrinogen concentration (β = −0.22, p = 0.01) in women. No adjusted associations were observed for Gal-3, DKK-1 or IL32 concentration. The study revealed no significant associations between the biomarkers and cIMT or cPP. The measurement of CST and fet-A levels could enhance RA patient management and prognosis. However, the utility of biomarkers for evaluating CV risk via traditional surrogate markers is limited, highlighting the need for continued investigations into their roles in RA.

show abstract

Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Cited by 2 publications

References 39 publications

Gut Microbiome and Its Role in Valvular Heart Disease: Not a “Gutted” Relationship

Gut Microbiome and Its Role in Valvular Heart Disease: Not a “Gutted” Relationship

Enhanced Association of Novel Cardiovascular Biomarkers Fetuin-A and Catestatin with Serological and Inflammatory Markers in Rheumatoid Arthritis Patients

Contact Info

Product

Resources

About